EPHA2 and gastric cancer: Flow cytometry showed that EPHA2 knockdown decreased EPHA2 levels by 76.6%–78.2% and 53.8%–55.2% in AGS and MKN45 cells, respectively, and inhibited Ephrin A1 binding by 79.5%–82.9% and 72.2%–79.7%, respectively (Fig. 4b), indicating that EPHA2 is the predominant EPH receptor for Ephrin A1-Fc in gastric cancer cells.